Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 434

1.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.

Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5.

PMID:
10744594
[PubMed - indexed for MEDLINE]
2.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

PMID:
11098244
[PubMed - indexed for MEDLINE]
Free Article
3.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

PMID:
12124837
[PubMed - indexed for MEDLINE]
Free Article
4.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

PMID:
11058616
[PubMed - indexed for MEDLINE]
Free Article
5.

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.

Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD.

Urology. 1997 Jan;49(1):71-8.

PMID:
9000189
[PubMed - indexed for MEDLINE]
6.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
[PubMed - indexed for MEDLINE]
7.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
[PubMed - indexed for MEDLINE]
8.

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.

Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, Bennett CL.

Urology. 2001 Apr;57(4):727-32.

PMID:
11306391
[PubMed - indexed for MEDLINE]
9.

Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.

Marks LS.

Urology. 2003 Dec 22;62(6 Suppl 1):36-42. Review.

PMID:
14706507
[PubMed - indexed for MEDLINE]
10.

Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.

Moul JW, Fowler JE Jr.

Urology. 2003 Dec 22;62(6 Suppl 1):20-8.

PMID:
14706505
[PubMed - indexed for MEDLINE]
11.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

PMID:
16544313
[PubMed - indexed for MEDLINE]
Free Article
12.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
[PubMed - indexed for MEDLINE]
13.

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.

Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM.

J Clin Oncol. 2001 Sep 1;19(17):3750-7.

PMID:
11533098
[PubMed - indexed for MEDLINE]
Free Article
14.

Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.

See WA.

Curr Treat Options Oncol. 2003 Oct;4(5):351-62. Review.

PMID:
12941195
[PubMed - indexed for MEDLINE]
15.

Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.

Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.

J Steroid Biochem. 1986 Nov;25(5B):877-83.

PMID:
3100871
[PubMed - indexed for MEDLINE]
16.

Is the flare phenomenon clinically significant?

Bubley GJ.

Urology. 2001 Aug;58(2 Suppl 1):5-9. Review.

PMID:
11502435
[PubMed - indexed for MEDLINE]
17.
18.

Hormone therapy of prostatic bone metastases.

Huben RP.

Adv Exp Med Biol. 1992;324:305-16.

PMID:
1492625
[PubMed - indexed for MEDLINE]
19.

Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.

Mariani AJ, Glover M, Arita S.

J Urol. 2001 Jan;165(1):104-7.

PMID:
11125375
[PubMed - indexed for MEDLINE]
20.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2001 Jan 15;19(2):343-53.

PMID:
11208825
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk